Eph receptors as therapeutic targets in glioblastoma

B. W. Day, B. W. Stringer, A. W. Boyd

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

The dismal outlook for patients with the most aggressive and common form of adult brain cancer, glioblastoma (GBM), motivates a search for new therapeutic strategies and targets for this aggressive disease. Here we review the findings to date on the role of Eph family receptor tyrosine kinases and their ephrin ligands in brain cancer. Expression of the Eph family of cell surface proteins is generally downregulated to very low levels in normal adult tissues making them particularly attractive for directed therapeutic targeting. Recent Eph targeting studies in pre-clinical models of GBM have been very encouraging and may provide an avenue to treat these highly refractory aggressive tumours.

Original languageEnglish
Pages (from-to)1255-1261
Number of pages7
JournalBritish Journal of Cancer
Volume111
Issue number7
DOIs
Publication statusPublished - 23 Sep 2014
Externally publishedYes

Bibliographical note

This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/

Keywords

  • Eph receptors
  • brain cancer
  • glioma
  • glioblastoma (GBM)
  • therapeutic targeting

Fingerprint Dive into the research topics of 'Eph receptors as therapeutic targets in glioblastoma'. Together they form a unique fingerprint.

  • Cite this